NEW YORK (GenomeWeb) – Roche today said that its Cobas HIV-1 and HCV next-generation viral load monitoring assays have received CE marking.

The Cobas HIV-1 assay simultaneously amplifies and detects two separate regions of the HIV-1 genome to quantify the amount of viral RNA in the patient's blood. The Cobas HCV assay employs the firm's dual-probe approach to detect hepatitis C RNA. Both assays are available for use on the Cobas 6800 and 8800 systems.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.